Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PTGIR | P43119 | 4/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 2/20 | 0.35 |
| ▸ | RXRB | P28702 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL361200 | 1.00 | LTB4R (0.39) | LTB4RALDH1A1MAPTPTGIRFFAR4 | |
| SCHEMBL360807 | 1.00 | LTB4R (0.39) | LTB4RALDH1A1MAPTPTGIRFFAR4 | |
| SCHEMBL15110410 | 1.00 | LTB4R (0.39) | LTB4RALDH1A1MAPTPTGIRFFAR4 | |
| SCHEMBL15110756 | 1.00 | LTB4R (0.39) | LTB4RALDH1A1MAPTPTGIRFFAR4 | |
| Hydrochloric Acid SCHEMBL15110833 | 0.99 | LTB4R (0.39) | LTB4RALDH1A1MAPTPTGIRFFAR4 | |
| SCHEMBL363395 | 0.97 | LTB4R (0.44) | LTB4RALDH1A1MAPTPTGIRRXRA | |
| SCHEMBL361581 | 0.97 | LTB4R (0.44) | LTB4RALDH1A1MAPTPTGIRRXRA | |
| Sulfuric Acid SCHEMBL15110406 | 0.96 | LTB4R (0.37) | LTB4RALDH1A1MAPTPTGIRFFAR4 | |
| SCHEMBL15110851 | 0.95 | ALDH1A1 (0.39) | LTB4RALDH1A1MAPTPTGIRGAA | |
| SCHEMBL15111305 | 0.95 | PKM (0.41) | LTB4RALDH1A1MAPTPTGIRFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4620525-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS | Respira Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250195855-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | GLAS USA LLC | 2025-06-19 | — | — | US | disclosed |
| US-20250195531-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS | Respira Therapeutics, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-12263174-B2 | Methods and compositions for treatment of pulmonary hypertension and other lung disorders | Respira Therapeutics, Inc. (US) | 2025-04-01 | — | — | US | disclosed |
| EP-4493258-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | Biora Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-119173296-A | Ingestible devices for delivering therapeutic agents to the gastrointestinal tract | 比奥拉治疗股份有限公司 | 2024-12-20 | — | — | CN | disclosed |
| EP-3870261-B1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | BIORA THERAPEUTICS INC (US) | 2024-01-31 | — | — | EP | disclosed |
| EP-4309722-A2 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | Biora Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023178354-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | BIORA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230149315-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | GLAS USA LLC | 2023-05-18 | — | — | US | disclosed |
| CN-115666704-A | Ingestible device for delivery of therapeutic agents to the gastrointestinal tract | 比奥拉治疗股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-11491161-B2 | Methods and compositions for treatment of pulmonary hypertension and other lung disorders | Respira Therapeutics, Inc. (US) | 2022-11-08 | — | — | US | disclosed |
| US-11491160-B2 | Methods and compositions for treatment of pulmonary hypertension and other lung disorders | Respira Therapeutics, Inc. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220347183-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS | Respira Therapeutics, Inc. (US) | 2022-11-03 | — | — | US | disclosed |
| US-20220079949-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS | Respira Therapeutics, Inc. (US) | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | MUC1, SLC10A2, FABP2 | LTB4R 304/4885ALDH1A1 2415/4885MAPT 3032/4885 |
| US-20230149315-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | MUC1, SLC10A2, FABP2 | LTB4R 304/4885ALDH1A1 2415/4885MAPT 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.